Key result
In patients with end-stage liver disease undergoing percutaneous coronary intervention, those with severe thrombocytopenia and elevated portal pressure have the highest bleeding risk.
Why the study?
There is no solid evidence for dual antiplatelet therapy in patients with cirrhosis undergoing percutaneous coronary intervention.
Is dual antiplatelet therapy safe and effective after percutaneous coronary interventions in patients with end-stage liver disease?
Is dual antiplatelet therapy safe and effective after percutaneous coronary interventions in patients with end-stage liver disease?
In patients with cirrhosis undergoing PCI, short-duration DAPT (one month) with contemporary DES via radial access is suggested to minimize bleeding risks.
Short DAPT may be feasible post-PCI in cirrhosis; leaves open need for prospective RCTs to confirm safety.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ostojić et al. (2021) conducted a review in End-stage liver disease and coronary artery disease. Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was evaluated. In patients with end-stage liver disease undergoing percutaneous coronary intervention, those with severe thrombocytopenia and elevated portal pressure have the highest bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: